Addressing Antigen Escape With CD19/20 Bispecific CAR
What is the CD19/20 Bispecific CAR
Chimeric antigen receptor (CAR) T cell therapies are now benefiting many patients with hematological malignancies with very high overall response rates.
However, despite this early success of anti-CD19 CAR T therapy, disease relapse poses a significant challenge because only about 40% of patients have durable complete remission.
At ImmPACT Bio, we are exploring next-generation CAR T cell therapies to improve outcomes for these patients.
What causes disease relapse
A major cause of disease relapse is CD19 antigen loss post CAR T therapy.
ImmPACT’s CD19/20 Bispecific CAR will help prevent relapse
To overcome this, ImmPACT Bio has developed a dual-targeted CAR T cell therapy that recognizes more than one antigen to prevent relapse. ImmPACT’s lead clinical-stage program employs a bispecific CAR that has been meticulously engineered to optimally target both CD19 and CD20, two antigens present on B-cell lymphoma.
A phase-I clinical trial evaluating this novel anti-CD19/CD20 CAR T cell therapy to treat relapsed/refractory B-cell lymphoma is continuing to recruit patients.
Here is how our CD19/20 CAR technology works
